{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:23:06Z","timestamp":1770895386635,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB-PG-1014-35052"],"award-info":[{"award-number":["PB-PG-1014-35052"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2851-9","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T15:38:20Z","timestamp":1535557100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-9671","authenticated-orcid":false,"given":"Duneesha","family":"de Fonseka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Stadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Ashley","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Dangoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Comins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Edey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick A.","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"2851_CR1","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841\u20138.","journal-title":"J Thorac Oncol"},{"key":"2851_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"2851_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"2851_CR4","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9:2643\u201358.","journal-title":"Curr Pharm Des"},{"key":"2851_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.ju.0000070685.34760.5f","volume":"170","author":"GM Oades","year":"2003","unstructured":"Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol. 2003;170:246\u201352.","journal-title":"J Urol"},{"key":"2851_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","volume":"38","author":"M Gnant","year":"2012","unstructured":"Gnant M, Clezardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407\u201315.","journal-title":"Cancer Treat Rev"},{"key":"2851_CR7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","volume":"19","author":"IJ Diel","year":"2008","unstructured":"Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;19:2007\u201311.","journal-title":"Ann Oncol"},{"key":"2851_CR8","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8:R13.","journal-title":"Breast Cancer Res"},{"key":"2851_CR9","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-05-2766","volume":"12","author":"S Wakchoure","year":"2006","unstructured":"Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res. 2006;12:2862\u20138.","journal-title":"Clin Cancer Res"},{"key":"2851_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lungcan.2004.06.003","volume":"47","author":"S Matsumoto","year":"2005","unstructured":"Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2005;47:31\u20139.","journal-title":"Lung Cancer"},{"key":"2851_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.lungcan.2007.08.026","volume":"59","author":"YY Li","year":"2008","unstructured":"Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180\u201391.","journal-title":"Lung Cancer"},{"key":"2851_CR12","first-page":"39","volume":"8","author":"MO Jamil","year":"2017","unstructured":"Jamil MO, Jerome MS, Miley D, Selander KS, Robert F. A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma. Lung Cancer (Auckl). 2017;8:39\u201344.","journal-title":"Lung Cancer (Auckl)"},{"key":"2851_CR13","doi-asserted-by":"publisher","first-page":"e0118569","DOI":"10.1371\/journal.pone.0118569","volume":"10","author":"AO Clive","year":"2015","unstructured":"Clive AO, Hooper CE, Edey AJ, Morley AJ, Zahan-Evans N, Hall D, et al. A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study. PLoS One. 2015;10:e0118569.","journal-title":"PLoS One"},{"key":"2851_CR14","doi-asserted-by":"publisher","first-page":"A89","DOI":"10.1136\/thoraxjnl-2016-209333.155","volume":"71","author":"AC Bibby","year":"2016","unstructured":"Bibby AC, De Fonseka D, Morley AJ, Keenan E, Addeo A, Smith S, et al. Exploring the characteristics of patients with mesothelioma who decline chemotherapy: a prospective cohort of 200 patients. Thorax. 2016;71:A89\u201390.","journal-title":"Thorax"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2851-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2851-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2851-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T14:44:36Z","timestamp":1568904276000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2851-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2851"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2851-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"4 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and related documents were reviewed by East of England Cambridge East Research Ethics Committee (Ref 16\/EE\/0105). All participants will be asked for written consent before enrolling in the study. Participants will be given sufficient time to read the PIL and ask any questions relating to the study before consenting. Participants will also have the right to withdraw from the study at any time without having to give reason, if they change their mind regarding participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"467"}}